Given the growing recognition of the roles played by VEGFR1 signaling [5] and PlGF [21] in pathological processes associated with angiogenic ocular conditions, targeting VEGFR1 activity may present an opportunity for the development of a human gene therapy for AMD and DR. This evidence concerns the gene FLT1 and age-related macular degeneration.